Ascendia

  MARKET NEWS

Phathom Pharmaceuticals Announces Submission of 6-Month Stability Data in Support of Erosive GERD NDA
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 Clinical Trial of Ninerafaxstat in Patients With Stable Angina
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer
Avidity Biosciences Receives FDA Orphan Drug Designation for for Treatment of Duchenne Muscular Dystrophy in People With Mutations Amenable to Exon 44 Skipping
Biostax Corp Announces FDA Acceptance of Three Investigational New Drug Applications Transfers for JKB-122 for the Treatment of NASH, NAFLD, and AIH
Ketabon GmbH Reports Top-Line Results From Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Actylis is a leading manufacturer of critical raw materials and performance ingredients serving the Life Sciences industry. Through our hybrid approach we provide combined capabilities in GMP manufacturing and global sourcing of critical raw materials and ingredients, offering unrivaled choice to pharmaceutical & biopharmaceutical companies. The inherent flexibility in our hybrid approach alleviates common internal customer concerns over time constraints in delivery to market and capacity pressures. We enable customers to consolidate their supply chain with one reliable partner, backed by best-in-class quality and regulatory accreditation, while retaining valuable flexibility. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Recipharm & Honeywell to Speed Development of Inhalers With Near-Zero Global Warming Potential Propellant

Recipharm & Honeywell to Speed Development of Inhalers With Near-Zero Global Warming Potential Propellant

Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care….

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

Tiziana Life Sciences Ltd. recently announced the US FDA has cleared the IND application for intranasal foralumab to be studied in Alzheimer’s disease. Foralumab could be a potentially….

BioCorRx Submits Expanded Access Treatment Protocol to FDA for Implantable Biodegradable Naltrexone Pellet for Opioid Use Disorder Treatment

BioCorRx Submits Expanded Access Treatment Protocol to FDA for Implantable Biodegradable Naltrexone Pellet for Opioid Use Disorder Treatment

Company hopes in 30 days to begin making its drug candidate available to help patients and address public health crisis….

Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

Clinigen Limited has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing

Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for

…

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability, solubility, …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER -  Long-Acting Injectable Nanoparticle Formulations

WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations

Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

What’s In This Whitepaper?

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 30 – Gene Therapy
September 6 – API Synthesis